Docetaxel and radiotherapy and pancreatic cancer

Pancreas

Volumn 27, Issue 3, 2003, Pages 214-219

  Viret, Frédéric ^a   Ychou, M ^c   Goncalves A ^a,b   Moutardier, V ^a   Magnin, V ^a   Braud, A C ^a   Dubois, J B ^c   Bories, E ^a   Gravis, G ^a   Camerlo, J ^a   Genre, D ^a   Maraninchi, D ^a,b   Viens, P ^a,b   Giovannini, M ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Concomitant radiotherapy; Locally advanced adenocarcinoma of the pancreas; Weekly docetaxel

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INDUCED EMESIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TAXOIDS; TIME FACTORS;

EID: 10744227556     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200310000-00003     Document Type: Article

References (34)

1. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221:721-731.
2. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Int J Radiat Oncol Biol Phys. 1991;5:1275-1279.
3. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447-458.
4. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37:1519-1524.
5. Pilepich M, Miller H. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980;46:1945-1949,
6. Group GTS. Therapy of locally unresected pancreatic carcinoma: a randomized comparaison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouacil), and high dose radiation + 5-fluorouacil. Cancer. 1981;48:1705-1710.
7. Group GTS. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
8. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantages of combined chemotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. Cancer. 2000;89:314-327.
9. Kastl S, Brunner T, Herrmann O, et al. Neadjuvant radio-chemotherapy in advanced primarylon-resectable carcinomas of the pancreas. Eur J Cancer. 2000;26:578-582.
10. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001;7:2246-2253.
11. Safran H, King TP, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study. J Clin Oncol. 1997;15:901-907.
12. Ringel I, Horwitz S. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288-291.
13. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff M, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991;34:992-998.
14. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 1998;10:123-30.
15. Goncalves A, Braguer D, Carles G, Andre N, Prevot C, Briand C. Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol. 2000;60:1579-1584.
16. Goncalves A, Braguer D, Kamath K, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA. 2001;98:11737-11742.
17. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9(Suppl 1):12-26.
18. Hennequin C, Giocanti NVF. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842-1850.
19. Mason K, Hunter N, Milas M, Abbruzzese J, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;3:2431-2438.
20. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res. 1999;5:4191-4198.
21. Pradier O, Rave-Fränk M, Lehmann J, et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASK1). Int J Cancer. 2001;91:840-845.
22. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253-1255.
23. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998;16:159-164.
24. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escaladation trial. Eur J Cancer. 1998;34:838-844.
25. Androulakis N, Kourousis C, Dimopoulos MA, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase study. J Clin Oncol. 1999;17:1779-1785.
26. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016-1025.
27. Vokes EE, Masters GA, Mauer AM, Haraf DJ, Hoffman PC, Golomb HM. Clinical studies of docetaxel (Taxotere) and recomittant chest therapy. Semin Oncol. 1997;24(Suppl 14):S14-29.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
29. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation = 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710.
30. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol. 1999;26(Suppl 9):32-36.
31. Burstein HJ, Manola J, Younger J, et al. Docetaxel administration on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212-1219.
32. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458-1467.
33. Vokes EE, Mauer AM, Hoffman PC, Haraf DJ. Combined modality therapy in non-small cell lung and esophageal cancer: A phase I dose-escaladation study of docetaxel with concurrent radiotherapy. Semin in Oncol. 1998;25(Suppl 8):28-32.
34. Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat OncolBio Phys. 2001;49:1275-1279.